2Suppliers
3Customers
3Debt Items
10Related Chains

Source-Backed Evidence Depth

Emergent BioSolutions Inc. (EBS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

9Total relationships
1Distinct source URLs
5High confidence
0.798Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Emergent BioSolutions Inc. Suppliers

TickerNameConfidenceEvidence
OHA-AGENCY-LLC OHA-AGENCY-LLC 90% Prior Term Loan Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto
SABS SAB Biotherapeutics, Inc. 72% Reciprocal relationship from SABS graph: gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate…

Emergent BioSolutions Inc. Customers

TickerNameConfidenceEvidence
VXRT Vaxart, Inc. 72% Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, produ…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% any’s management utilizes segment adjusted gross margin and segment adjusted gross margin percentage for purposes of evaluating our ongoing operations and for internal planning and forecasting purpos…
HIKMA-PHARMACEUTICALS-INC HIKMA-PHARMACEUTICALS-INC 62% or implied by the forward-looking statements contained in the following discussion and analysis. BUSINESS OVERVIEW Emergent BioSolutions Inc. (“Emergent,” the “Company,” “we,” “us,” and “our”) is a g…

Emergent BioSolutions Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
EBS-DEBT-9208 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
EBS-DEBT-9207 Warrants outstanding: 5500000 90% xbrl warrant detail from xbrl 2025-12-31.
EBS-DEBT Debt stack $581.8M 90% Market cache reports total debt of $581.8M.

Emergent BioSolutions Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Emergent BioSolutions Inc..

Emergent BioSolutions Inc. Ownership

HolderNameConfidenceEvidence
EBS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 192 tracked holders.

Emergent BioSolutions Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SNYNF Sanofi 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
VXRT Vaxart, Inc. 100.00 1 ['customer']
COCP Cocrystal Pharma, Inc. 50.00 2
SGIOF Shionogi & Co., Ltd. 50.00 2
MRK Merck & Co., Inc. 50.00 2
HCRP HCRP 50.00 2
CSLLY CSL Limited 50.00 2
FTRE Fortrea Holdings Inc. 50.00 2
SABS SAB Biotherapeutics, Inc. 36.29 1 ['supplier']
🔐
EBS
Unlock EBS Supply Chain Data
Verified relationships include:
OHA-AGENCY-LLCOHA-AGENCY-LLCSupplier90%
SABSSAB Biotherapeutics, Inc.Supplier72%
VXRTVaxart, Inc.Customer72%
CAPITAL-RESOURCESCAPITAL-RESOURCESCustomer62%
+5 more relationships locked
Subscribe — View plans →